Update 1: Biotech, Drug Stocks Up on Week
629222
Investors expecting a formal vote from a Food and Drug Administration panel Friday on Eyetech Pharmaceuticals Inc.&#39;s age-related blindness treatment Macugen may have been disappointed as shares of the stock fell after the meeting.
593483
The Nikkei average rose 1.9 percent by  midsession on Monday as banks extended last week's gains and  strong gains in U.S. semiconductor chip stocks helped push up  Japanese peers such as Advantest Corp.
302848
U.S. stocks rose on Monday as a slew of acquisition deals pointed to optimism about the economy, outweighing sharp losses by blue-chip Pfizer Inc. , which dropped a key experimental drug.
47271
Stocks rose on Thursday, led by industrial and pharmaceutical shares, as investors turned defensive ahead of jobs data that could show how much housing and tight credit markets may have damaged the economy.
709400
Stocks edged up for the week, continuing a month-long rally in the face of mediocre economic news and more-positive developments from technology firms and energy markets.
421295
U.S. stocks rose on Monday as several major corporate deals pointed to optimism about the economy, outweighing sharp losses by blue-chip Pfizer Inc.  after the world's No. 1 drug company dropped a key experimental product.
585524
U.S. stocks rallied on Tuesday, with  the Dow closing at its highest level in 3 1/2 years, boosted by  a rebound in beaten-down drugmaker Pfizer Inc. PFE.N, while  tech stocks got a lift from a broker upgrade of Intel Corp.  INTC.O.
227799
Drugmakers Merck & Co.  and Schering-Plough Corp.  reported second-quarter results that handily topped Wall Street expectations on Monday, helped by increased sales of the cholesterol-lowering drugs they co-market and other medicines.
9086
Stocks inched higher Tuesday as investors saw the bright side of mixed economic data and rumors about big merger deals, including a report that consumer products giant Johnson &amp; Johnson&#39;s is in talks to purchase a leading medical device maker.
603802
Shares in BioCrist (BCRX :Nasdaq - news - research) jumped in premarket trading Tuesday after regulators granted orphan status to the company&#39;s lead anti-cancer drug, forodesine hydrochloride, boosting the Alabama-based biotech&#39;s prospects.
334517
The stock market rose for the week as upbeat economic news offset concerns about inflation and interest rates.
520141
Shares in biotechnology company Gilead Sciences Inc  could climb another 20 percent to 25 percent on strong demand for its existing AIDS and flu drugs as well as from new products in the pipeline, Barron's reported in its July 9 issue.
121618
Stocks climbed on Friday, with gains  on all three major indexes topping 1 percent, as strong results  from Research in Motion lifted the technology sector while a  report of another overseas investment in a U.S. investment bank  boosted financial stocks.
34170
LOS ANGELES (CBS.MW) -- Shares of Gilead Sciences climbed Thursday, touching a 52-week high at one point, after the biotechnology firm reported positive results from its recently approved HIV drug Truvada.
329654
U.S. stock indexes gained on Monday as takeover news and strong profits from large-cap companies, such as Merck & Co. , reassured investors after a broad sell-off at the end of last week.
644015
Biotechnology stocks moved higher Wednesday, led by MGI Pharma Inc., which agreed to buy a stake in SuperGen Inc. as part of a licensing deal for SuperGen&#39;s Dacogen drug.
601397
Stocks inched higher Tuesday as investors saw the bright side of mixed economic data and rumors about big merger deals, including a report that consumer products giant Johnson &amp; Johnson is in talks to purchase a leading medical device maker.